Table 1.
Demographic and clinical data of patients in analysis.
| Patients without progression (n = 64) | Patients who progressed (n = 61) | p value | ||
|---|---|---|---|---|
| Age (years, SD) | 69.3 (8.29) | 69.6 (6.82) | 0.85 | |
| Gender (n, %) | Female | 10 (55.5) | 8 (44.4) | 0.68 |
| Male | 54 (50.47) | 53 (49.53) | ||
| Smoking status (n, %) | Yes | 24 (41.38) | 34 (58.62) | 0.04 |
| No | 40 (59.7) | 27 (40.3) | ||
| Stage (n %) | Ta | 36 (67.9) | 17 (32) | 0.001 |
| T1 | 28 (38.8) | 44 (61.1) | ||
| Grade (n, %) | LG | 42 (60.8) | 27 (39.1) | 0.01 |
| HG | 22 (39.2) | 34 (60.7) | ||
| Observational time (months, SD) | 24.6 (19.1) | 22.4 (24.2) | 0.55 | |
| LMR (n, SD) | 3.87 (2.1) | 2.71 (1.03) | <0.001 | |
| PLR (n, SD) | 137.7 (77) | 133.7 (56) | 0.74 | |
| NLR (n, SD) | 3.07 (2.18) | 3.23 (1.88) | 0.65 | |
LMR, lymphocyte to monocyte ratio; PLR, platelet to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio.